{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:01:19Z","timestamp":1789268479548,"version":"build-2803163510"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100005150","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2017-I2M-3-004"],"award-info":[{"award-number":["2017-I2M-3-004"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2019-I2M-1-003"],"award-info":[{"award-number":["2019-I2M-1-003"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2020,9,28]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Ubiquitin specific protease 48 (USP48) is a member of the deubiquitinating\nenzymes (DUBs) family. However, the function of USP48 in ovarian cancer remains unclear. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present study reveals that USP48 knockdown could significantly inhibit cell migration\nand invasion in ES2, 3AO and A2780 cells, without affecting cell proliferation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> After carboplatin (CBP) treatment, the USP48 ablation increases the apoptosis rate, and\nthe cleaved PARP and cleaved caspase 3 expression levels in ES2, 3AO and A2780 cells. The subcutaneous\ntumor and intraperitoneally injected experiments demonstrated that the USP48 knockdown\nsignificantly increases responsiveness to CBP, and alleviates the metastasis in vivo. Meanwhile,\nUSP48 deficiency results in the improved survival of mice. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Finally, the analysis of clinical samples and the TCGA and Kaplan-Meier Plot database revealed\nthat the high expression of USP48 in ovarian cancer patients is associated with poor survival\nand resistance to CBP therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In summary, USP48 may be a potential therapeutic target for ovarian cancer patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009620666200503045400","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T06:30:02Z","timestamp":1588487402000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1827","authenticated-orcid":true,"given":"Xuemeng","family":"Lei","sequence":"first","affiliation":[{"name":"Guizhou University, School of Medicine, Guiyang, Guizhou 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-6873","authenticated-orcid":true,"given":"Xukun","family":"Li","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-6100","authenticated-orcid":true,"given":"Hongyan","family":"Chen","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5005-0522","authenticated-orcid":true,"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"Siegel R.L.","year":"2018","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2018. CA Cancer J Clin 2018,68(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/path.4536","volume":"236","author":"Leong H.S.","year":"2015","unstructured":"Leong H.S.; Galletta L.; Etemadmoghadam D.; George J.; K\u00f6bel M.; Ramus S.J.; Bowtell D.; Australian ovarian cancer study. Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol 2015,236(3),272-277","journal-title":"J Pathol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.cell.2018.03.073","volume":"173","author":"Zhang A.W.","year":"2018","unstructured":"Zhang A.W.; McPherson A.; Milne K.; Kroeger D.R.; Hamilton P.T.; Miranda A.; Funnell T.; Little N.; de Souza C.P.E.; Laan S.; LeDoux S.; Cochrane D.R.; Lim J.L.P.; Yang W.; Roth A.; Smith M.A.; Ho J.; Tse K.; Zeng T.; Shlafman I.; Mayo M.R.; Moore R.; Failmezger H.; Heindl A.; Wang Y.K.; Bashashati A.; Grewal D.S.; Brown S.D.; Lai D.; Wan A.N.C.; Nielsen C.B.; Huebner C.; Tessier-Cloutier B.; Anglesio M.S.; Bouchard-Cote A.; Yuan Y.; Wasserman W.W.; Gilks C.B.; Karnezis A.N.; Aparicio S.; McAlpine J.N.; Huntsman D.G.; Holt R.A.; Nelson B.H.; Shah S.P.; interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 2018,173(7),1755-1769","journal-title":"Cell"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"Jayson G.C.","year":"2014","unstructured":"Jayson G.C.; Kohn E.C.; Kitchener H.C.; Ledermann J.A.; Ovarian cancer. Lancet 2014,384(9951),1376-1388","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"Agarwal R.","year":"2003","unstructured":"Agarwal R.; Kaye S.B.; Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003,3(7),502-516","journal-title":"Nat Rev Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"Harrigan J.A.","year":"2018","unstructured":"Harrigan J.A.; Jacq X.; Martin N.M.; Jackson S.P.; Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov 2018,17(1),57-78","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.molcel.2016.05.009","volume":"63","author":"Abdul Rehman S.A.","year":"2016","unstructured":"Abdul Rehman S.A.; Kristariyanto Y.A.; Choi S.Y.; Nkosi P.J.; Weidlich S.; Labib K.; Hofmann K.; Kulathu Y.; mindy-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol Cell 2016,63(1),146-155","journal-title":"Mol Cell"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41418-019-0339-0","volume":"27","author":"Wu X.","year":"2020","unstructured":"Wu X.; Luo Q.; Zhao P.; Chang W.; Wang Y.; Shu T.; Ding F.; Li B.; Liu Z.; JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. Cell Death Differ 2020,27(1),55-70","journal-title":"Cell Death Differ"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1073\/pnas.1814742116","volume":"116","author":"Wu X.","year":"2019","unstructured":"Wu X.; Luo Q.; Zhao P.; Chang W.; Wang Y.; Shu T.; Ding F.; Li B.; Liu Z.; MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. Proc Natl Acad Sci USA 2019,116(8),2961-2966","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41467-018-04649-z","volume":"9","author":"Velimezi G.","year":"2018","unstructured":"Velimezi G.; Robinson-Garcia L.; Mu\u00f1oz-Mart\u00ednez F.; Wiegant W.W.; Ferreira da Silva J.; Owusu M.; Moder M.; Wiedner M.; Rosenthal S.B.; Fisch K.M.; Moffat J.; Menche J.; van Attikum H.; Jackson S.P.; Loizou J.I.; Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48. Nat Commun 2018,9(1),2280","journal-title":"Nat Commun"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1158\/0008-5472.CAN-17-4052","volume":"78","author":"Ye S.","year":"2018","unstructured":"Ye S.; Lawlor M.A.; Rivera-Reyes A.; Egolf S.; Chor S.; Pak K.; Ciotti G.E.; Lee A.C.; Marino G.E.; Shah J.; Niedzwicki D.; Weber K.; Park P.M.C.; Alam M.Z.; Grazioli A.; Haldar M.; Xu M.; Perry J.A.; Qi J.; Eisinger-Mathason T.S.K.; YAP1-mediated suppression of USP31 enhances NF\u03baB activity to promote sarcomagenesis. Cancer Res 2018,78(10),2705-2720","journal-title":"Cancer Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"Allemani C.","year":"2018","unstructured":"Allemani C.; Matsuda T.; Di Carlo V.; Harewood R.; Matz M.; Nik\u0161i\u0107 M.; Bonaventure A.; Valkov M.; Johnson C.J.; Est\u00e8ve J.; Ogunbiyi O.J.; Azevedo E.; Silva, G.; Chen, W.Q.; Eser, S.; Engholm, G.; Stiller, C.A.; Monnereau, A.; Woods, R.R.; Visser, O.; Lim, G.H.; Aitken, J.; Weir, H.K.; Coleman, M.P. CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018,391(10125),1023-1075","journal-title":"Lancet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","volume":"160","author":"Zhao J.","year":"2016","unstructured":"Zhao J.; Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther 2016,160,145-158","journal-title":"Pharmacol Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"x69","DOI":"10.1093\/annonc\/mdt475","volume":"24","author":"Lopez J.","year":"2013","unstructured":"Lopez J.; Banerjee S.; Kaye S.B.; New developments in the treatment of ovarian cancer-future perspectives. Ann Oncol 2013,24(Suppl. 10),x69-x76","journal-title":"Ann Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1073\/pnas.1013715108","volume":"108","author":"Patel A.G.","year":"2011","unstructured":"Patel A.G.; Sarkaria J.N.; Kaufmann S.H.; Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA 2011,108(8),3406-3411","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"Ledermann J.","year":"2012","unstructured":"Ledermann J.; Harter P.; Gourley C.; Friedlander M.; Vergote I.; Rustin G.; Scott C.; Meier W.; Shapira-Frommer R.; Safra T.; Matei D.; Macpherson E.; Watkins C.; Carmichael J.; Matulonis U.; Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012,366(15),1382-1392","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166]","volume":"474","author":"Bell D.","year":"2011","unstructured":"Bell D.; Berchuck A.; Birrer M.; Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011,474(7353),609-615","journal-title":"Nature"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"Bolton K.L.","year":"2012","unstructured":"Bolton K.L.; Chenevix-Trench G.; Goh C.; Sadetzki S.; Ramus S.J.; Karlan B.Y.; Lambrechts D.; Despierre E.; Barrowdale D.; McGuffog L.; Healey S.; Easton D.F.; Sinilnikova O.; Ben\u00edtez J.; Garc\u00eda M.J.; Neuhausen S.; Gail M.H.; Hartge P.; Peock S.; Frost D.; Evans D.G.; Eeles R.; Godwin A.K.; Daly M.B.; Kwong A.; Ma E.S.; L\u00e1zaro C.; Blanco I.; Montagna M.; D\u2019Andrea E.; Nicoletto M.O.; Johnatty S.E.; Kj\u00e6r S.K.; Jensen A.; H\u00f8gdall E.; Goode E.L.; Fridley B.L.; Loud J.T.; Greene M.H.; Mai P.L.; Chetrit A.; Lubin F.; Hirsh-Yechezkel G.; Glendon G.; Andrulis I.L.; Toland A.E.; Senter L.; Gore M.E.; Gourley C.; Michie C.O.; Song H.; Tyrer J.; Whittemore A.S.; McGuire V.; Sieh W.; Kristoffersson U.; Olsson H.; Borg \u00c5.; Levine D.A.; Steele L.; Beattie M.S.; Chan S.; Nussbaum R.L.; Moysich K.B.; Gross J.; Cass I.; Walsh C.; Li A.J.; Leuchter R.; Gordon O.; Garcia-Closas M.; Gayther S.A.; Chanock S.J.; Antoniou A.C.; Pharoah P.D.; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012,307(4),382-390","journal-title":"JAMA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5301\/tj.5000558","volume":"102","author":"McLachlan J.","year":"2016","unstructured":"McLachlan J.; George A.; Banerjee S.; The current status of PARP inhibitors in ovarian cancer. Tumori 2016,102(5),433-440","journal-title":"Tumori"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"Coleman R.L.","year":"2017","unstructured":"Coleman R.L.; Oza A.M.; Lorusso D.; Aghajanian C.; Oaknin A.; Dean A.; Colombo N.; Weberpals J.I.; Clamp A.; Scambia G.; Leary A.; Holloway R.W.; Gancedo M.A.; Fong P.C.; Goh J.C.; O\u2019Malley D.M.; Armstrong D.K.; Garcia-Donas J.; Swisher E.M.; Floquet A.; Konecny G.E.; McNeish I.A.; Scott C.L.; Cameron T.; Maloney L.; Isaacson J.; Goble S.; Grace C.; Harding T.C.; Raponi M.; Sun J.; Lin K.K.; Giordano H.; Ledermann J.A.; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017,390(10106),1949-1961","journal-title":"Lancet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"Moore K.","year":"2018","unstructured":"Moore K.; Colombo N.; Scambia G.; Kim B.G.; Oaknin A.; Friedlander M.; Lisyanskaya A.; Floquet A.; Leary A.; Sonke G.S.; Gourley C.; Banerjee S.; Oza A.; Gonz\u00e1lez-Mart\u00edn A.; Aghajanian C.; Bradley W.; Mathews C.; Liu J.; Lowe E.S.; Bloomfield R.; DiSilvestro P.; Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018,379(26),2495-2505","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"Lambert A.W.","year":"2017","unstructured":"Lambert A.W.; Pattabiraman D.R.; Weinberg R.A.; Emerging biological principles of metastasis. Cell 2017,168(4),670-691","journal-title":"Cell"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"Nieto M.A.","year":"2016","unstructured":"Nieto M.A.; Huang R.Y.; Jackson R.A.; Thiery J.P.; EMT: 2016. Cell 2016,166(1),21-45","journal-title":"Cell"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2010.11.011","volume":"73","author":"Chung J.H.","year":"2011","unstructured":"Chung J.H.; Rho J.K.; Xu X.; Lee J.S.; Yoon H.I.; Lee C.T.; Choi Y.J.; Kim H-R.; Kim C.H.; Lee J.C.; Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2011,73(2),176-182","journal-title":"Lung Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2174\/15680096113136660097","volume":"13","author":"Shang Y.","year":"2013","unstructured":"Shang Y.; Cai X.; Fan D.; Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets 2013,13(9),915-929","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.ymthe.2018.04.002","volume":"26","author":"Lin Z.","year":"2018","unstructured":"Lin Z.; L.; Sun, S.; Xie, S.; Zhang, S.; Fan, Q.; Li, W.; Chen, G.; Pan, W.; Wang, B.; Weng, Z.; Zhang, B.; Liu, J. Chemotherapy-induced long non-coding RNA 1 promotes metastasis and chemo-resistance of TSCC via the Wnt\/beta-catenin signaling pathway. Mol Ther 2018,26(6),1494-1508","journal-title":"Mol Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.lungcan.2016.12.012","volume":"104","author":"Sesumi Y.","year":"2017","unstructured":"Sesumi Y.; Suda K.; Mizuuchi H.; Kobayashi Y.; Sato K.; Chiba M.; Shimoji M.; Tomizawa K.; Takemoto T.; Mitsudomi T.; Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. Lung Cancer 2017,104,85-90","journal-title":"Lung Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015891","volume":"6","author":"Luise C.","year":"2011","unstructured":"Luise C.; Capra M.; Donzelli M.; Mazzarol G.; Jodice M.G.; Nuciforo P.; Viale G.; Di Fiore P.P.; Confalonieri S.; An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 2011,6(1)","journal-title":"PLoS One"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1038\/s41467-019-10824-7","volume":"10","author":"Du T.","year":"2019","unstructured":"Du T.; Li H.; Fan Y.; Yuan L.; Guo X.; Zhu Q.; Yao Y.; Li X.; Liu C.; Yu X.; Liu Z.; Cui C.P.; Han C.; Zhang L.; The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. Nat Commun 2019,10(1),2914","journal-title":"Nat Commun"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/ncb2874","volume":"15","author":"Zhang J.","year":"2013","unstructured":"Zhang J.; Zhang P.; Wei Y.; Piao H.L.; Wang W.; Maddika S.; Wang M.; Chen D.; Sun Y.; Hung M.C.; Chen J.; Ma L.; Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol 2013,15(12),1486-1494","journal-title":"Nat Cell Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1172\/JCI73733","volume":"124","author":"Diefenbacher M.E.","year":"2014","unstructured":"Diefenbacher M.E.; Popov N.; Blake S.M.; Sch\u00fclein-V\u00f6lk C.; Nye E.; Spencer-Dene B.; Jaenicke L.A.; Eilers M.; Behrens A.; The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. J Clin Invest 2014,124(8),3407-3418","journal-title":"J Clin Invest"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.15252\/embr.201643124","volume":"18","author":"Zhou A.","year":"2017","unstructured":"Zhou A.; Lin K.; Zhang S.; Ma L.; Xue J.; Morris S.A.; Aldape K.D.; Huang S.; Gli1-induced deubiquitinase USP48 aids glioblastoma tumorigenesis by stabilizing Gli1. EMBO Rep 2017,18(8),1318-1330","journal-title":"EMBO Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"43180","DOI":"10.1038\/srep43180","volume":"7","author":"Cetkovsk\u00e1 K.","year":"2017","unstructured":"Cetkovsk\u00e1 K.; \u0160ustov\u00e1 H.; Uldrijan S.; Ubiquitin-specific peptidase 48 regulates Mdm2 protein levels independent of its deubiquitinase activity. Sci Rep 2017,7,43180","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2017.09.048","volume":"411","author":"Shu T.","year":"2017","unstructured":"Shu T.; Li Y.; Wu X.; Li B.; Liu Z.; Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. Cancer Lett 2017,411,65-73","journal-title":"Cancer Lett"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181584\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/181584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T06:09:06Z","timestamp":1613714946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181584\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009620666200503045400","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}